Evidence map›Paper›PMID 28881672›Full record

ArticleOncotarget2017

MB4-2/MB4-3 transcripts of

Feng Li, Yong-Ping Zhai, Ting Lai, Qian Zhao, Hui Zhang, Yu-Mei Tang, Jian Hou

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Cancers · 2024
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. The effect of novel therapies in high-molecular-risk multiple myeloma.Clinical advances in hematology & oncology : H&O · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Feng LiMyeloma and Lymphoma Center, Department of Hematology, Changzheng Hospital, The Second Military Medical University, Shanghai, China.
Yong-Ping ZhaiDepartment of Hematology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Ting LaiDepartment of Hematology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Qian ZhaoDepartment of Hematology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Hui ZhangMyeloma and Lymphoma Center, Department of Hematology, Changzheng Hospital, The Second Military Medical University, Shanghai, China.
Yu-Mei TangDepartment of Hematology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Jian HouMyeloma and Lymphoma Center, Department of Hematology, Changzheng Hospital, The Second Military Medical University, Shanghai, China.
Nanjing General Hospital of Nanjing Military Command · CNSecond Military Medical University · CNNanjing University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) patients with t(4;14) is a heterogeneous group. Prognostic tools capable of predicting the outcome of patients are currently lacking. The MM SET domain (MMSET) protein is universally overexpressed and has been suggested to have an important tumorigenic role. This study analyzed whether the overexpression of full-length (MB4-1) or truncated forms (MB4-2 and MB4-3) of

Indexed as

bortezomibmajor breakpoint (MB4)MMSET geneprognosist(4;14) translocation

Identifiers

PMID28881672
PMCPMC5584273
OpenAlexW2620101707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.